Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and (18)F-FDG-PET imaging

Disease-modifying treatment trials are increasingly advanced to the prodromal or preclinical phase of Alzheimer's disease (AD), and inclusion criteria are based on biomarkers rather than clinical symptoms. Therefore, it is of great interest to determine which biomarkers should be combined to ac...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Neuroimage Clin
Huvudupphovsmän: Ottoy, Julie, Niemantsverdriet, Ellis, Verhaeghe, Jeroen, De Roeck, Ellen, Struyfs, Hanne, Somers, Charisse, wyffels, Leonie, Ceyssens, Sarah, Van Mossevelde, Sara, Van den Bossche, Tobi, Van Broeckhoven, Christine, Ribbens, Annemie, Bjerke, Maria, Stroobants, Sigrid, Engelborghs, Sebastiaan, Staelens, Steven
Materialtyp: Artigo
Språk:Inglês
Publicerad: Elsevier 2019
Ämnen:
Regular Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6444289/
https://ncbi.nlm.nih.gov/pubmed/30927601
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.nicl.2019.101771
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk